Clinical Trials Browser

Phase 1/2 × talimogene laherparepvec × 90 days × Clear all

NCT02779855 2026-03-10

Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer

Phase 1/2 Completed

50 enrolled 12 charts

Breast Neoplasms, Carcinoma, Ductal, Breast, Carcinoma, Ductal, Triple Negative Breast Neoplasms

NCT04599062 2026-01-29

TVEC and Preop Radiation for Sarcoma (8 ml Dose)

Phase 1/2 Active not recruiting

8 enrolled 8 charts

Sarcoma